Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
Buy
57
NOVT Quote, Financials, Valuation and Earnings
Last price:
$138.06
Seasonality move
:
13.03%
Day range:
$134.11 - $138.68
52-week range:
$133.17 - $187.12
Dividend yield:
0%
P/E ratio:
77.52x
P/S ratio:
5.25x
P/B ratio:
6.65x
Volume:
137.9K
Avg. volume:
245.7K
1-year change:
-20.36%
Market cap:
$5B
Revenue:
$949.2M
EPS (TTM):
$1.78
Analysts' Opinion
-
Consensus RatingNovanta has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $161.11, Novanta has an estimated upside of 16.77% from its current price of $137.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $138.34 representing 100% downside risk from its current price of $137.98.
Fair Value
-
According to the consensus of 3 analysts, Novanta has 16.77% upside to fair value with a price target of $161.11 per share.
NOVT vs. S&P 500
-
Over the past 5 trading days, Novanta has underperformed the S&P 500 by -3.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novanta does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novanta has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Novanta reported revenues of $238.1M.
Earnings Growth
-
Novanta has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Novanta reported earnings per share of $0.46.
Enterprise value:
5.3B
EV / Invested capital:
4.53x
Price / LTM sales:
5.25x
EV / EBIT:
42.36x
EV / Revenue:
5.55x
PEG ratio (5yr expected):
--
EV / Free cash flow:
37.24x
Price / Operating cash flow:
35.26x
Enterprise value / EBITDA:
29.27x
Gross Profit (TTM):
$421.5M
Return On Assets:
4.68%
Net Income Margin (TTM):
6.75%
Return On Equity:
9.04%
Return On Invested Capital:
5.55%
Operating Margin:
13.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $860.9M | $881.7M | $949.2M | $211.6M | $238.1M | |
| Gross Profit | $378.5M | $399.9M | $421.5M | $96.6M | $108.2M | |
| Operating Income | $107.5M | $123.3M | $124.3M | $26.3M | $33.1M | |
| EBITDA | $160.6M | $169.9M | $179.9M | $37.8M | $47.5M | |
| Diluted EPS | $2.07 | $2.02 | $1.78 | $0.34 | $0.46 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $304.2M | $373.8M | $420.5M | $415.3M | $433.6M | |
| Total Assets | $865.2M | $1.2B | $1.2B | $1.2B | $1.4B | |
| Current Liabilities | $114.2M | $183.9M | $164.5M | $139.2M | $167.8M | |
| Total Liabilities | $388.4M | $706.6M | $663.6M | $552.6M | $642.8M | |
| Total Equity | $476.8M | $521.3M | $577.6M | $673.5M | $745.7M | |
| Total Debt | $200.4M | $434.5M | $435.5M | $354.4M | $416.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $90.8M | $120.1M | $158.5M | $39M | $61.6M | |
| Cash From Investing | -$42.5M | -$19.9M | -$208.2M | -$6.2M | -$2.1M | |
| Cash From Financing | -$60.2M | -$97.9M | $56.9M | -$5.1M | -$35.6M | |
| Free Cash Flow | $69.7M | $100.1M | $141.4M | $32.8M | $59.3M | |
NOVT
Sector
Market Cap
$5B
$91.6M
Price % of 52-Week High
73.74%
60%
Dividend Yield
0%
0%
Shareholder Yield
--
0.82%
1-Year Price Total Return
-20.36%
-15.91%
Beta (5-Year)
1.339
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$138.46
200-day SMA
Sell
Level
$164.29
Bollinger Bands (100)
Sell
Level
144.67 - 170.23
Chaikin Money Flow
Buy
Level
36.8M
20-day SMA
Sell
Level
$142.03
Relative Strength Index (RSI14)
Sell
Level
41.76
ADX Line
Sell
Level
30.16
Williams %R
Neutral
Level
-75.986
50-day SMA
Sell
Level
$146.24
MACD (12, 26)
Sell
Level
-3.13
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
4.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.6032)
Buy
CA Score
(Annual)
Level (0.4449)
Buy
Beneish M-Score
(Annual)
Level (-2.7115)
Sell
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.3639)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Stock Forecast FAQ
In the current month, NOVT has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NOVT average analyst price target in the past 3 months is $161.11.
-
Where Will Novanta Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novanta share price will rise to $161.11 per share over the next 12 months.
-
What Do Analysts Say About Novanta?
Analysts are divided on their view about Novanta share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novanta is a Sell and believe this share price will drop from its current level to $138.34.
-
What Is Novanta's Price Target?
The price target for Novanta over the next 1-year time period is forecast to be $161.11 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NOVT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novanta is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NOVT?
You can purchase shares of Novanta via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novanta shares.
-
What Is The Novanta Share Price Today?
Novanta was last trading at $138.06 per share. This represents the most recent stock quote for Novanta. Yesterday, Novanta closed at $137.98 per share.
-
How To Buy Novanta Stock Online?
In order to purchase Novanta stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
48
SMTC alert for Mar 18
Semtech [SMTC] is down 1.01% over the past day.
Buy
67
PLPC alert for Mar 18
Preformed Line Products [PLPC] is up 0.87% over the past day.
Buy
58
NUTX alert for Mar 18
Nutex Health [NUTX] is down 1.31% over the past day.
